指南与共识临床试验与 GCP医学教育与科研方法

安慰剂对照手术试验的患者信息手册:现行实践综述及对开发者的建议

Patient information leaflets for placebo-controlled surgical trials: a review of current practice and recommendations for developers.
指南 / 共识 · Trials · 2024-05-22

该综述旨在调查近期完成的侵入性操作(含手术)安慰剂对照试验的患者信息手册(PIL)关键内容,从近期系统综述纳入的试验中获取PIL,对62项合格随机对照试验中可联系的59项试验作者索取,最终收到14份PIL进行分析。结果显示,至少50%的PIL包含一般试验设计内容,43%解释了安慰剂与手术干预的异同,57%包含手术干预的潜在治疗获益信息,仅7%包含安慰剂侵入性成分的潜在间接治疗获益信息,36%呈现安慰剂已知风险,57%呈现手术干预已知风险。作者建议PIL开发者仔细考虑用语(如sham、mock),明确说明安慰剂与手术干预的异同,并分别平衡呈现手术干预与安慰剂的潜在获益和风险。

要点

  • 14份PIL中6份(43%)解释了安慰剂与手术干预的异同。
  • 8份(57%)呈现手术干预已知风险,5份(36%)呈现安慰剂已知风险。
  • 仅1份(7%)包含安慰剂侵入性成分的潜在间接治疗获益信息。

核心结论

  • 安慰剂对照手术试验的PIL开发者应仔细考虑用语(如sham、mock),明确说明安慰剂与手术干预的异同,并分别平衡呈现手术干预与安慰剂的潜在获益和风险。
  • 需要进一步研究以确定设计和提供此类试验信息的最佳方法。

研究设计与样本

  • 从近期一项关于侵入性操作(含手术)安慰剂对照试验的系统综述所纳入的试验中获取PIL。
  • 62项合格随机对照试验中,59项试验的作者可联系,最终收到14份PIL用于分析。
  • 提取试验特征及所评估手术和安慰剂干预的数据,采用定向内容分析法,参考已发表的PIL内容监管与良好实践指南及现有安慰剂对照手术试验研究。
  • 结果采用描述性统计并以叙述性总结呈现。

主要发现

  • 至少50%的PIL包含一般试验设计内容。
  • 6份(43%)PIL报告了安慰剂与手术干预如何不同或相似(即保真度)的解释。
  • 超过一半(57%)的PIL包含手术干预潜在治疗获益的信息。
  • 1份(7%)PIL包含安慰剂侵入性成分潜在间接治疗获益的信息。
  • 5份(36%)PIL呈现安慰剂干预的已知风险,8份(57%)PIL呈现手术干预的已知风险;PIL中用于描述安慰剂成分的术语包括「control」「mock」和「sham」。

临床怎么用

  • 作者建议安慰剂对照手术试验的PIL开发者应仔细考虑用语(如sham、mock),明确说明安慰剂与手术干预的异同,并分别平衡呈现手术干预与安慰剂的潜在获益和风险。

局限性

  • 62项合格随机对照试验中仅从14项试验获得PIL用于分析。
  • 需要进一步研究以确定设计和提供此类试验信息的最佳方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Informed consent for participation in an RCT is an important ethical and legal requirement. In placebo surgical trials, further issues are raised, and to date, this has not been explored. Patient information leaflets (PILs) are a core component of the informed consent process. This study aimed to investigate the key content of PILs for recently completed placebo-controlled trials of invasive procedures, including surgery, to highlight areas of good practice, identify gaps in information provision for trials of this type and provide recommendations for practice. METHODS: PILs were sought from trials included in a recent systematic review of placebo-controlled trials of invasive procedures, including surgery. Trial characteristics and data on surgical and placebo interventions under evaluation were extracted. Directed content analysis was applied, informed by published regulatory and good practice guidance on PIL content and existing research on placebo-controlled surgical trials. Results were analysed using descriptive statistics and presented as a narrative summary. RESULTS: Of the 62 eligible RCTs, authors of 59 trials were contactable and 14 PILs were received for analysis. At least 50% of all PILs included content on general trial design. Explanations of how the placebo differs or is similar to the surgical intervention (i.e. fidelity) were reported in 6 (43%) of the included PILs. Over half (57%) of the PILs included information on the potential therapeutic benefits of the surgical intervention. One (7%) included information on potential indirect therapeutic benefits from invasive components of the placebo. Five (36%) presented the known risks of the placebo intervention, whilst 8 (57%) presented information on the known risks of the surgical intervention. A range of terms was used across the PILs to describe the placebo component, including 'control', 'mock' and 'sham'. CONCLUSION: Developers of PILs for placebo-controlled surgical trials should carefully consider the use of language (e.g. sham, mock), be explicit about how the placebo differs (or is similar) to the surgical intervention and provide balanced presentations of potential benefits and risks of the surgical intervention separately from the placebo. Further research is required to determine optimal approaches to design and deliver this information for these trials.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Cousins S, Huttman M, Blencowe N, et al. Patient information leaflets for placebo-controlled surgical trials: a review of current practice and recommendations for developers. Trials. 2024. PMID: 38778336. doi:10.1186/s13063-024-08166-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。